Nanobac Pharmaceuticals Incorporated Stock Price To Book
| NNBP Stock | USD 0.0001 0.00 0.000003% |
Nanobac Pharmaceuticals Incorporated fundamentals help investors to digest information that contributes to Nanobac Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Nanobac Stock. The fundamental analysis module provides a way to measure Nanobac Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nanobac Pharmaceuticals stock.
As of 03/20/2025, Price To Book Ratio is likely to drop to -22.03. Nanobac | Price To Book |
Nanobac Pharmaceuticals Incorporated Company Price To Book Analysis
Nanobac Pharmaceuticals' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Nanobac Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Nanobac Pharmaceuticals is extremely important. It helps to project a fair market value of Nanobac Stock properly, considering its historical fundamentals such as Price To Book. Since Nanobac Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nanobac Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nanobac Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Nanobac Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Nanobac Pharmaceuticals Incorporated has a Price To Book of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to book for all United States stocks is 100.0% higher than that of the company.
Nanobac Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nanobac Pharmaceuticals' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nanobac Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Nanobac Pharmaceuticals by comparing valuation metrics of similar companies.Nanobac Pharmaceuticals is currently under evaluation in price to book category among its peers.
Nanobac Fundamentals
| Return On Asset | -0.37 | ||||
| Operating Margin | (151.42) % | ||||
| Current Valuation | 124.75 K | ||||
| Price To Earning | (0.02) X | ||||
| Price To Sales | 7.08 X | ||||
| Revenue | 17.62 K | ||||
| Gross Profit | 3.1 K | ||||
| EBITDA | (3.97 M) | ||||
| Net Income | (6.58 M) | ||||
| Cash And Equivalents | 3.93 K | ||||
| Total Debt | 4.12 M | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (910.89 K) | ||||
| Beta | -38.01 | ||||
| Market Capitalization | 124.75 K | ||||
| Total Asset | 7.22 M | ||||
| Retained Earnings | (28.93 M) | ||||
| Working Capital | (6.71 M) | ||||
| Current Asset | 31 K | ||||
| Current Liabilities | 6.75 M | ||||
| Net Asset | 7.22 M |
About Nanobac Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanobac Pharmaceuticals Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanobac Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanobac Pharmaceuticals Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.